{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:22:40Z","timestamp":1773310960833,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12328-024-02055-1","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:07:25Z","timestamp":1730884045000},"page":"220-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["S-1\/irinotecan\/oxaliplatin\u00a0chemotherapy achieved a pathological complete remission in advanced pancreatic carcinoma"],"prefix":"10.1007","volume":"18","author":[{"given":"Ru","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-4499","authenticated-orcid":false,"given":"Tomohisa","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Okuwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2055_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/00365521.2022.2067786","volume":"57","author":"R Andersson","year":"2022","unstructured":"Andersson R, Haglund C, Sepp\u00e4nen H, et al. Pancreatic cancer \u2013 the past, the present, and the future. Scand J Gastroenterol. 2022;57:1169\u201377.","journal-title":"Scand J Gastroenterol"},{"key":"2055_CR2","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.3390\/cancers15092584","volume":"15","author":"M S\u0142odkowski","year":"2023","unstructured":"S\u0142odkowski M, Wro\u0144ski M, Karkocha D, et al. Current approaches for the curative-intent surgical treatment of pancreatic ductal adenocarcinoma. Cancers (Basel). 2023;15:2584.","journal-title":"Cancers (Basel)"},{"key":"2055_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607\u201320.","journal-title":"Lancet"},{"key":"2055_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/medicina54030048","volume":"54","author":"L Hajatdoost","year":"2018","unstructured":"Hajatdoost L, Sedaghat K, Walker EJ, et al. Chemotherapy in pancreatic cancer: a systematic review. Medicina (Kaunas). 2018;54:48.","journal-title":"Medicina (Kaunas)"},{"key":"2055_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/jcm8111945","volume":"8","author":"T Hank","year":"2019","unstructured":"Hank T, Strobel O. Conversion surgery for advanced pancreatic cancer. J Clin Med. 2019;8:1945.","journal-title":"J Clin Med"},{"key":"2055_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2022.06.010","volume":"174","author":"A Ohba","year":"2022","unstructured":"Ohba A, Ueno H, Shiba S, et al. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: a multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer. 2022;174:40\u20137.","journal-title":"Eur J Cancer"},{"key":"2055_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.48147","volume":"5","author":"H Topal","year":"2022","unstructured":"Topal H, Aerts R, Laenen A, et al. Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma. JAMA Netw Open. 2022;5: e2248147.","journal-title":"JAMA Netw Open"},{"key":"2055_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12893-023-02091-7","volume":"23","author":"M Di Martino","year":"2023","unstructured":"Di Martino M, El Boghdady M. Pancreatic cancer surgery. BMC Surg. 2023;23:196.","journal-title":"BMC Surg"},{"key":"2055_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/OP.2023.19.11_suppl.23","volume":"19","author":"J Yan","year":"2023","unstructured":"Yan J, Davendra PSS. Pancreatic adenocarcinoma management. JCO Oncol Pract. 2023;19:23.","journal-title":"JCO Oncol Pract"},{"key":"2055_CR10","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838\u201348.","journal-title":"Clin Cancer Res"},{"key":"2055_CR11","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.21037\/jtd.2018.05.68","volume":"10","author":"W Schreiner","year":"2018","unstructured":"Schreiner W, Gavrychenkova S, Dudek W, et al. Pathologic complete response after induction therapy-the role of surgery in stage IIIA\/B locally advanced non-small cell lung cancer. J Thorac Dis. 2018;10:2795\u2013803.","journal-title":"J Thorac Dis"},{"key":"2055_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","volume":"268","author":"J He","year":"2018","unstructured":"He J, Blair AB, Groot VP, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268:1\u20138.","journal-title":"Ann Surg"},{"key":"2055_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00535-020-01666-y","volume":"55","author":"T Okusaka","year":"2020","unstructured":"Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369\u201382.","journal-title":"J Gastroenterol"},{"key":"2055_CR14","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.3892\/or.2013.2795","volume":"30","author":"G Galizia","year":"2013","unstructured":"Galizia G, De Vita F, Lieto E, et al. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncol Rep. 2013;30:2992\u20138.","journal-title":"Oncol Rep"},{"key":"2055_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12957-020-01954-0","volume":"18","author":"R Matsumoto","year":"2020","unstructured":"Matsumoto R, Arigami T, Matsushita D, et al. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol. 2020;18:179.","journal-title":"World J Surg Oncol"},{"key":"2055_CR16","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.21037\/jgo.2018.01.07","volume":"9","author":"AM Luu","year":"2018","unstructured":"Luu AM, Herzog T, Hoehn P, et al. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol. 2018;9:E9\u201312.","journal-title":"J Gastrointest Oncol"},{"key":"2055_CR17","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","volume":"34","author":"A Ohba","year":"2023","unstructured":"Ohba A, Ozaka M, Ogawa G, et al. 16160 nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase II\/III trial. Ann Oncol. 2023;34:S894.","journal-title":"Ann Oncol"},{"key":"2055_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/SLA.0000000000003570","volume":"274","author":"AB Blair","year":"2021","unstructured":"Blair AB, Yin LD, Pu N, et al. Recurrence in patients achieving pathological complete response after neoadjuvant treatment for advanced pancreatic cancer. Ann Surg. 2021;274:162\u20139.","journal-title":"Ann Surg"},{"key":"2055_CR19","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.3390\/cancers12082036","volume":"12","author":"M Lee","year":"2020","unstructured":"Lee M, Kwon W, Kim H, et al. The role of location of tumor in the prognosis of the pancreatic cancer. Cancers. 2020;12:2036.","journal-title":"Cancers"},{"key":"2055_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3389\/fonc.2019.01501","volume":"9","author":"U Klaiber","year":"2019","unstructured":"Klaiber U, Hackert T. Conversion surgery for pancreatic cancer-the impact of neoadjuvant treatment. Front Oncol. 2019;9:1501.","journal-title":"Front Oncol"},{"key":"2055_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1634\/theoncologist.2018-0900","volume":"24","author":"T Akahori","year":"2019","unstructured":"Akahori T, Sho M, Yanagimoto H, et al. Phase II study of the triple combination chemotherapy of SOXIRI (S-1\/Oxaliplatin\/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Oncologist. 2019;24:749-e224.","journal-title":"Oncologist"},{"key":"2055_CR22","doi-asserted-by":"publisher","first-page":"175883592097084","DOI":"10.1177\/1758835920970843","volume":"12","author":"K Nie","year":"2020","unstructured":"Nie K, Zhang L, You Y, et al. Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Ther Adv Med Oncol. 2020;12:1758835920970843.","journal-title":"Ther Adv Med Oncol"},{"key":"2055_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.pan.2023.12.008","volume":"24","author":"F Wang","year":"2024","unstructured":"Wang F, Wang Y, Ren C, et al. Phase II study of SOXIRI (S-1\/oxaliplatin\/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Pancreatology. 2024;24:241\u20138.","journal-title":"Pancreatology"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-02055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-024-02055-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-02055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:17:02Z","timestamp":1738329422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-024-02055-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2055"],"URL":"https:\/\/doi.org\/10.1007\/s12328-024-02055-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}